Intercept Pharmaceuticals, Inc. Overview
Pro stress-test →Intercept Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). The company was acquired by Alfasigma S.p.A. in November 2023 for $19.00 per share in cash. The company's lead commercialized product is Ocaliva® (obeticholic acid).
Strategic Profile
Pro stress-test →Intercept delivered strong double-digit growth of Ocaliva as of Q2 2023, with the company positioned as a leader in rare and serious liver disease therapeutics. The development pipeline includes INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist. Following its acquisition by Alfasigma, the company's assets are now integrated into a larger European pharmaceutical conglomerate with expanded gastrointestinal and hepatology capabilities.
Competitive Landscape
Pro stress-test →Intercept competes in the rare liver disease market against companies developing FXR agonists and other hepatology-focused therapeutics. The company's pipeline includes dual and single FXR/TGR5 mechanism candidates (INT-767, INT-777), positioning it against other FXR-based programs. Primary competitors in this space include Gilead Sciences (FXR program development), Viking Therapeutics (VK2735), and Madrigal Pharmaceuticals (Resmetirom for NASH).
Industry Context
Intercept Pharmaceuticals, Inc. operates in Specialty pharmaceuticals for rare liver diseases.
Key facts
Founded: 2002 · Headquarters: Morristown, New Jersey, US · Employees: unknown · Revenue: $320–$340M · Market cap: $794.7M